Five-year outcome of a randomised trial comparing second-generation drug-eluting stents using either biodegradable polymer or durable polymer: the NOBORI biolimus-eluting versus XIENCE/PROMUS everolimus-eluting stent trial (NEXT)

EuroIntervention 2018;14:815-818 published online February 2018. DOI: 10.4244/EIJ-D-17-01050

Masahiro Natsuaki
Masahiro Natsuaki1, MD; Ken Kozuma2, MD; Takeshi Morimoto3, MD; Kazushige Kadota4, MD; Toshiya Muramatsu5, MD; Yoshihisa Nakagawa6, MD; Takashi Akasaka7, MD; Keiichi Igarashi Hanaoka8, MD; Kengo Tanabe9, MD; Yoshihiro Morino10, MD; Hideo Nishikawa11, MD; Takeshi Kimura12*, MD
1. Department of Cardiovascular Medicine, Saga University, Saga, Japan; 2. Division of Cardiology, Teikyo University Hospital, Tokyo, Japan; 3. Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan; 4. Department of Cardiology

In the meta-analysis of randomised clinical trials comparing the safety and efficacy of a biodegradable polymer drug-eluting stent (BP-DES) as compared with new-generation durable polymer drug-eluting stents (DP-DES), no sign

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Stents and scaffolds
Read next article
Incidence of procedural myocardial infarction and cardiac magnetic resonance imaging-detected myocardial injury following percutaneous coronary intervention with rotational atherectomy

Latest news